Aim 1 is to determine whether DBS in the periaqueductal/periventricular gray region (PAG/PVG) of the brain at analgesic intensities produces any systemic or neurological adverse effects in patients with longstanding SCI (>1 year), either immediately or as a result of prolonged application for up 40 weeks.